ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0548

Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis

David Kiefer1, Juergen Braun2, Uta Kiltz3, Niklas Kolle1, Lucia Schneider1, Ioana Andreica4, Bjoern Buehring5, Philipp Sewerin6, Imke Redeker7, Styliani Tsiami8, Susanne Herbold9 and Xenofon Baraliakos8, 1Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 5Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, 6Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ruhr Universität Bochum, Bochum, Germany, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Herne, Germany

Meeting: ACR Convergence 2024

Keywords: Disease Activity, health status, Patient reported outcomes, physical activity, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity.
To investigate the impact of kinesiophobia on patients with axial spondylo-arthritis (axSpA), and its relation to global functioning and health, disease activity, function, spinal mobility and physical activity in comparison to healthy controls (HC).                                                                                                         

Methods: Post-hoc analysis of an observational study in which consecutive patients with axSpA (n=100) and 20 healthy controls (HC) were examined by the Tampa scale of kinesiophobia (TSK), and the Fear avoidance belief questionnaire (FABQ). Patient reported outcomes and objective assessments of disease activity (ASDAS, BASDAI), physical function (BASFI), global health and functioning (ASAS HI), daily level of physical activity  (mSQUASH) as well as the BASMI, the AS physical performance index (ASPI) and the Short Physical Performance Battery (SPPB) were collected. Categorical analysis to differentiate results of patients with minimal/low (TSK ≤ 28) and moderate/high (TSK >28) kinesiophobia as well as linear correlations comparing TSK and FABQ with demographic data and clinical assessments were performed.

Results: While demographic data for age, sex and BMI were comparable, patients with axSpA showed higher TSK (25.5±6.8 vs 14.0±5.1) and FABQ scores (40.1±22.6 vs 3.1±6.9), worse results for pain, daily level of physical activity (p=0.001) and performance based tests compared to HC, all p≤ 0.001 (Table 1). Categorical analysis of kinesiophobia levels revealed that patients with moderate to high kinesiophobia performed significantly worse in ASPI (32.2±15.0 vs 42.0±18.3) and SPPB (10.4±1.3 vs 9.7±1.5), and showed numerical impairments in BASMI (3.8±1.7 vs 4.3±2.6), (Table 2). Significant correlations between TSK/FABQ and assessments were observed for ASAS HI (r=0.45 and r=0.52) and BASFI (r=0.38 and r=0.44), but not for ASPI, SPPB, mSQUASH. Weak correlations were found for BASMI (r=0.24 and r=0.38) and BASDAI scores (both r=0.35), see Table 3.

Conclusion: Kinesiophobia is a clinically relevant issue for patients with axSpA, with impaired mobility found in patients reporting moderate to high TSK and FABQ scores. The degree of kinesiophobia showed stronger correlations with physical function, global functioning and health than with mobility and physical activity.

Supporting image 1

*variables are mean ± standard deviation if not otherwise indicated; ASPI: the AS physical performance index; ASDAS: AS Disease Activity Score; SPPB: Short Physical Performance Battery, BASMI: Bath Ankylosing Spondylitis (AS) Metrology Index; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; CRP: C-reative protein; NSAIDs: Non-steroidal anti-inflammatory drugs; axSpA= axial spondyloarthritis; NRS = numerical rating scale; mSQUASH: the modified-Short QUestionnaire to Assess Health-enhancing physical activity; TSK: Tampa Scale for Kinesiophobia FABQ: Fear-Avoidance Beliefs Questionnaire; FABQ1: ‘physical activity’; FABQ2: ‘work as cause of pain’ FABQ3: ‘patients’ assumptions of their probable return to work’

Supporting image 2

*variables are mean ± standard deviation if not otherwise indicated; ASDAS: AS Disease Activity Score; BASMI: Bath Ankylosing Spondylitis (AS) Metrology Index; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; CRP: C-reative protein; r-axSpA = radiographic axial spondyloarthritis (axSpA); non-radiographic axSpA (nr-axSpA); NRS = numerical rating scale; mSQUASH: the modified-Short QUestionnaire to Assess Health-enhancing physical activity; TSK: Tampa Scale for Kinesiophobia FABQ: Fear-Avoidance Beliefs Questionnaire;

Supporting image 3

*p<0.05; ** =p <0.001; ***=p<0.0001; BMI = body mass index; bDMARD = biological Disease Modifying AntiRheumatic Drugs; CRP = C-reactive protein; NSAID = non-steroidal anti-inflammatory drugs; axSpA = axial spondyloarthritis; ASPI: the AS physical performance index; ASDAS: AS Disease Activity Score; SPPB: Short Physical Performance Battery, BASMI: Bath Ankylosing Spondylitis (AS) Metrology Index; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; axSpA= axial spondyloarthritis; mSQUASH: the modified-Short QUestionnaire to Assess Health-enhancing physical activity; TSK: Tampa Scale for Kinesiophobia FABQ: Fear-Avoidance Beliefs Questionnaire; FABQ1: 'physical activity'; FABQ2: 'work as cause of pain' FABQ3: 'patients' assumptions of their probable return to work'


Disclosures: D. Kiefer: AbbVie/Abbott, 6, Novartis, 6, UCB, 1, 6; J. Braun: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Celgene, 2, 5, 6, Celltrion, 2, 5, 6, Centocor, 2, 5, 6, Chugai, 2, 5, 6, Eli Lilly, 2, 5, 6, Medac, 2, 5, 6, MSD (Schering-Plough), 2, 5, 6, Mundipharma, 2, 5, Novartis, 2, 5, 6, Pfizer (Wyeth), 2, 5, 6, Roche, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, UCB, 2, 5, 6; U. Kiltz: AbbVie, 2, 5, 6, Amgen, 5, Biocad, 2, 6, Biogen, 5, Chugai, 2, 6, Eli Lilly, 2, 6, Fresenius, 5, 6, Grünenthal, 2, 6, GSK, 5, Hexal, 5, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 6, UCB, 2, 6; N. Kolle: None; L. Schneider: None; I. Andreica: None; B. Buehring: AbbVie/Abbott, 2, 6, 12, Travel reimbursement, Alexion, 2, Amgen, 2, 6, 12, Travel reimbursement, Biogen, 6, Boehringer-Ingelheim, 6, Gilead, 6, Janssen, 12, Travel reimbursement, Merck/MSD, 12, Travel reimbursement, Sanofi-Genzyme, 6, Theramex, 2, 6, 12, Travel reimbursement, UCB, 2, 6, 12, Travel reimbursement; P. Sewerin: AbbVie, 2, 6, Amgen, 2, 6, AXIOM Health, 2, Biogen, 2, 6, Bristol Myers Squibb, 2, 6, Celgene, 2, 6, Chugai, 2, Deutscher Psoriasis-Bund, 2, Eli Lilly, 2, 6, Gilead Sciences, 2, 6, Hexal Pharma, 2, 6, Janssen-Cilag, 2, 6, Johnson & Johnson, 2, 6, Mediri GmbH, 2, Novartis Pharma, 2, 6, Onkowissen GmbH, 2, Pfizer, 2, 6, Pharma Marketing Ltd/Chugai Europe, 2, Rheumazentrum Rhein-Ruhr, 2, 6, Roche Pharma, 2, 6, Sanofi-Genzyme, 2, 6, Spirit Medical Communication, 2, Swedish Orphan Biovitrum, 2, 6, UCB Pharma, 2, 6; I. Redeker: None; S. Tsiami: None; S. Herbold: None; X. Baraliakos: AbbVie, 2, 6, 12, Paid instructor, BMS, 2, 6, 12, Paid instructor, Chugai, 2, 6, 12, Paid instructor, Eli Lilly, 2, 6, 12, Paid instructor, Galapagos, 2, 6, 12, Paid instructor, Gilead, 2, MSD, 6, 12, Paid instructor, Novartis, 2, 5, 6, 12, Paid instructor, Pfizer, 2, 6, 12, Paid instructor, UCB Pharma, 2, 5, 6, 12, Paid instructor.

To cite this abstract in AMA style:

Kiefer D, Braun J, Kiltz U, Kolle N, Schneider L, Andreica I, Buehring B, Sewerin P, Redeker I, Tsiami S, Herbold S, Baraliakos X. Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-and-impact-of-kinesiophobia-on-patient-reported-outcomes-and-performance-based-mobility-measures-in-patients-with-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-and-impact-of-kinesiophobia-on-patient-reported-outcomes-and-performance-based-mobility-measures-in-patients-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology